本帖最后由 老马 于 2013-3-13 13:43 编辑
x4 |- O+ u) H
7 ~6 d C* ] ^/ I& j* J& B. P. ]健择（吉西他滨）+顺铂+阿瓦斯汀7 ]! N2 R$ j8 h* p. l) P
Gemzar +Cisplatin + Avastin5 `' _8 h* k' N* B8 B$ d. P3 K; t
http://annonc.oxfordjournals.org/content/21/9/1804.full- l: X3 P/ G( h( H; @6 w
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) : `% g5 z# \- F# n. d1 R8 I
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ) c4 X2 d: f" B2 o, W/ X0 w
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( I$ W' ~, g. j4 [" d
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 242)
1 l+ h& Y& p& S- {5 U s1 b: `/ j华为网盘附件：- O, @* Z% S: _; F% Z( j7 P: Y. a
【华为网盘】ava.JPG4 q; m6 {3 v$ L
|
显身卡
